CD163 and non-small cell lung carcinoma: Our study determined the expression of CD163, CD206, TGF-β, IL-10, and Arg-1 in the plasma of NSCLC patients and found that their expression was significantly upregulated in osimertinib-resistant plasma, which indicated the existence of M2 type TAMs in osimertinib-resistant plasma.